Halozyme Therapeutics HALO
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$17.23M (9 inflow days, 11 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 29.0% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 12.90% to 12.03% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Distillate Capital Partners LLC | Mutual Fund | 2026/Q3 | +149,323 | 0.1% |
| Two Sigma Investments, LP | Hedge Fund | 2026/Q4 | +1,865,872 | 3.1% |
| D. E. Shaw & Co., L.P. | Hedge Fund | 2026/Q4 | +1,367,027 | 3.0% |
| Congress Asset Management Company, LLP | Mutual Fund | 2026/Q4 | +1,052,509 | 2.0% |
| Wasatch Advisors LP | Mutual Fund | 2026/Q4 | +1,049,647 | 0.9% |
| Neuberger Berman Investment Advisers LLC | Mutual Fund | 2026/Q4 | +939,064 | 1.1% |
| Frontier Capital Management | Mutual Fund | 2026/Q4 | +852,151 | 1.0% |
| Jane Street Group, LLC | Private Company | 2026/Q4 | +823,999 | 1.3% |
| Marshall Wace LLP | Hedge Fund | 2026/Q4 | +552,920 | 0.7% |
| First Trust Advisors L.P. | Mutual Fund | 2026/Q4 | +400,761 | 1.6% |
| BlackRock | Mutual Fund | 2026/Q4 | +397,471 | 12.0% |
| Hudson River Trading LLC | Private Company | 2026/Q4 | +330,187 | 0.6% |
| FMR | Mutual Fund | 2026/Q4 | +328,841 | 0.3% |
| UBS Asset Management | Mutual Fund | 2026/Q4 | +324,746 | 1.9% |
| Invesco Ltd. | Mutual Fund | 2026/Q4 | +315,227 | 2.6% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 7 Oct 2026 | Helen Torley | Chief Executive Officer | Derivative Exercise and Sale | -60,000 | $113.69 | 767,780 |
| 30 Sep 2026 | James Daly | Director | Other Acquisition | +1,169 | – | 1,169 |
| 30 Sep 2026 | James Daly | Director | Other Derivative Acquisition | +1,775 | $106.94 | 1,775 |
| 30 Sep 2026 | Matthew Posard | Independent Director | Automatic Disposition | -5,230 | $110.04 | 49,813 |
| 15 Sep 2026 | Matthew Posard | Independent Director | Automatic Disposition | -18,996 | $108.99 | 55,043 |
| 10 Sep 2026 | Helen Torley | Chief Executive Officer | Derivative Exercise and Sale | -60,000 | $108.67 | 767,780 |
| 31 Aug 2026 | Dannielle Appelhans | Director | Other Acquisition | +1,161 | – | 1,161 |
| 31 Aug 2026 | Dannielle Appelhans | Director | Other Derivative Acquisition | +1,778 | $107.72 | 1,778 |
| 18 Aug 2026 | Helen Torley | Chief Executive Officer | Derivative Exercise and Sale | -60,000 | $107.77 | 767,780 |
| 9 Aug 2026 | Bernadette Connaughton | Independent Director | Automatic Disposition | -1,626 | $102.80 | 33,622 |
| 7 Jul 2026 | Helen Torley | Chief Executive Officer | Derivative Exercise and Sale | -1,923 | $80.19 | 767,780 |
| 30 Jun 2026 | David Ramsay | President of Drug Delivery | Other Derivative Acquisition | +16,232 | – | 16,232 |
| 30 Jun 2026 | David Ramsay | President of Drug Delivery | Other Derivative Acquisition | +39,823 | $77.01 | 39,823 |
| 30 Jun 2026 | Bernadette Connaughton | Independent Director | Automatic Disposition | -1,625 | $77.21 | 35,248 |
| 30 Jun 2026 | Darren Snellgrove | Senior Vice President | Other Derivative Acquisition | +41,554 | – | 41,554 |
| 30 Jun 2026 | Darren Snellgrove | Senior Vice President | Other Derivative Acquisition | +127,432 | $77.01 | 127,432 |
| 29 Jun 2026 | David Ramsay | President of Drug Delivery | Derivative Exercise and Sale | -5,408 | $78.27 | 4,592 |
| 29 Jun 2026 | David Ramsay | President of Drug Delivery | Derivative Exercise and Retained | +4,592 | – | 4,592 |
| 28 Jun 2026 | Mahesh Krishnan | Independent Director | Derivative Exercise and Sale | -7,304 | $75.00 | 10,666 |
| 11 Jun 2026 | Mark Snyder | Executive VP, General Counsel, Chief Compliance Officer & Corporate Secretary | Derivative Exercise and Sale | -2,715 | $69.50 | 49,929 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 13,650,219 | 12.0% | 6.8 |
| 15 Oct 2026 | 13,654,228 | 12.0% | 6.2 |
| 30 Sep 2026 | 15,295,841 | 13.5% | 4.5 |
| 15 Sep 2026 | 15,154,414 | 13.4% | 11.6 |
| 31 Aug 2026 | 14,880,707 | 13.1% | 8.7 |
| 14 Aug 2026 | 14,636,927 | 12.9% | 5.0 |
No comments yet — be the first to weigh in on HALO.
Sign in to join the discussion.